A game changer for chronic wounds, cancer, inflammatory diseases & beyond.
4-in-1 synthetic biology, cell and gene therapy platform
At Aurealis Therapeutics, we have built a unique multi-target cell and gene therapy platform to address unmet medical needs.
Discover the mode of action of our lead clinical asset AUP-16, a topical cell therapy that enables the healing of Diabetic Foot Ulcers (DFU) and other chronic, non-healing wounds.
THE TEAM, THE SCIENCE & the outcome
THE AUREALIS TEAM
At Aurealis Therapeutics we are passionate about our science to make a difference for patients. Meet the Management Team, the Scientific Advisory Board, the Board of Directors, and the Aurealis Therapeutics Team Members.
THE SCIENCE
Our team takes pride in mastering the most advanced cell and gene therapy science, and making work in real life, from the lab to pre-clinical and to the clinic.
THE OUTCOME
Generating pre-clinical, clinical and health-economic evidence is how we want to make a difference. Seeing non-healing wounds healing, seeing how cancer deaths can be prevented – this is what matters the most.
Aurealis Therapeutics Partner Xbiome Receives IND Approval from China’s National Medical Products Administration for the Phase 2 Study with AUP-16 in Diabetic Foot Ulcers
Xbiome announced that its Phase 2 study with AUP-16 (AUP1602-C) in diabetic foot ulcer has officially obtained IND approval from the National Medical Products Administration (NMPA) and the study can...
AUP-16: More cost-effective than the current Standard Of Care at healing Diabetic Foot Ulcers revealed at ISPOR Europe 2023
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, participated in ISPOR Europe Health Economics and Market Access conference...
Aurealis Therapeutics launches Venous Leg Ulcer (VLU) scientific expert group, an important step towards AUP-16 VLU phase 2 clinical trial
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announces the initiation of its Venous Leg Ulcer (VLU) scientific...
Aurealis Therapeutics presented advancements in multi-target bacterial gene therapies at the 14th International Symposium on Lactic Acid Bacteria
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, is making remarkable advances in the field with its 4-in-1...
Aurealis Therapeutics announces first patient dosed in DIAMEND Phase 2 Diabetic Foot Ulcer clinical trial of AUP-16
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announced today that the first diabetic foot ulcer (DFU) patient...
Aurealis Therapeutics shines in Nordic Life Science News with in-depth interview on gene therapy innovations
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, is excited to share its recent feature in the well-known...
